Fatal rhabdomyolysis and multiple organ failure associated with adjuvant high-dose interferon alfa in malignant melanoma [3]

Lancet

Volumn 349, Issue 9051, 1997, Pages 540-541

  Reinhold, Uwe ^a   Hartl, Christoph ^a   Hering, Rudolf ^a   Hoeft, Andreas ^a   Kreysel, Hans Wilhelm ^a  

^a UNIVERSITY OF BONN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CREATINE KINASE; DACARBAZINE; RECOMBINANT ALPHA INTERFERON; RECOMBINANT ALPHA2B INTERFERON;

ADULT; CANCER ADJUVANT THERAPY; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG MEGADOSE; FATALITY; HUMAN; HYPERKALEMIA; HYPERPHOSPHATEMIA; HYPOCALCEMIA; INGUINAL LYMPH NODE; INTRAVENOUS DRUG ADMINISTRATION; LETTER; LYMPH NODE METASTASIS; LYMPHADENECTOMY; MALE; MELANOMA; METABOLIC ACIDOSIS; MULTIPLE ORGAN FAILURE; MYALGIA; MYOGLOBINURIA; PRIORITY JOURNAL; RHABDOMYOLYSIS; SHOCK; SUBCUTANEOUS DRUG ADMINISTRATION; THROMBOCYTOPENIA;

EID: 0031049344     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(97)80091-8     Document Type: Article

References (3)

1. Kirkwood JM, Strawderman MH, Ernstoff MS, et al. Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol 1996; 14: 7-17.
2. Anderlini P, Buzaid AC, Legha SS. Acute rhabdomyolysis after concurrent administration of interleukin-2, interferon-alfa, and chemotherapy for metastatic melanoma. Cancer 1995; 76: 678-79.
3. Greenfield SM, Harvey RS, Thompson RPH. Rhabdomyolysis after treatment with interferon alfa. BMJ 1994; 309: 512.